Inhibition of angiogenesis in cancer patients

Bibliography

• CARMELIET P, JAIN RK: Angiogenesis in cancer and other diseases. Nature (2000) 407:249–257.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl. J. Med. (1995) 333:1757–1763.
   PubMed Web of Science ®Google Scholar
• VERHEUL HM, VOEST EE, SCHLINGEMANN RO: Are tumours angiogenesis-dependent? J. Pathol (2004) 202:5–13.
   Web of Science ®Google Scholar
• RIBATTI D, VACCA A, PRESTA M: Thediscovery of angiogenic factors: a historical review. Gen. Pharmacol (2000) 35:227–231.
   PubMedGoogle Scholar
• FOLKMAN J: What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. (1990) 82:4–6.
   Google Scholar
• GIMBRONE MA, LEAPMAN S B Jr, COTRAN RS, FOLKMAN J: Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. (1972) 136:261–276.
   PubMed Web of Science ®Google Scholar
• UDAGAWA T, FERNANDEZ A, ACHILLES EG, FOLKMAN J, D'AMATO RJ: Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J. (2002) 16:1361–1370.
   PubMed Web of Science ®Google Scholar
• •These investigators demonstrated in vivo proof of the angiogenic balance.
   Google Scholar
• HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86: 353–364.
   Google Scholar
• •In this landmark review the predinical research that has been performed is summarised, demonstrating the dogma that the balance of angiogenesis inhibitors and stimulators determine whether a tumour will grow.
   Google Scholar
• SCAPPATICCI FA: The therapeutic potential of novel antiangiogenic therapies. Expert Opin. Investig. Drugs (2003) 12:923–932.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Tumor angiogenesis: therapeutic implications. N Engl. J. Med. (1971) 285:1182–1186.
   PubMed Web of Science ®Google Scholar
• SCAPPATICCI FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. (2002) 20:3906–3927.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl. J. Med. (2004) 50:2335–2342.
   Web of Science ®Google Scholar
• •A landmark publication: the first randomised clinical trial showing activity of an angiogenesis inhibitor in clinical oncology.
   Google Scholar
• YANG JC, HAWORTH L, SHERRY R et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl. J. Med. (2003) 349:427–434.
   PubMed Web of Science ®Google Scholar
• KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol (2003) 21:60–65.
   PubMed Web of Science ®Google Scholar
• THORPE PE: Vascular targeting agents a cancer therapeutics. Clin. Cancer Res. (2004) 10(2):415–427.
   PubMed Web of Science ®Google Scholar
• FERRARA N, HILLAN KJ, GERBER HP, NOVOTNY W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. (2004) 3:391–400.
   PubMed Web of Science ®Google Scholar
• WILDIERS H, GUETENS G, DE BOECK G et al.: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer (2003) 88:1979–1986.
   PubMed Web of Science ®Google Scholar
• MARGOLIN K, GORDON MS, HOLMGREN E et al.: Phase lb trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol (2001) 19:851–856.
   PubMed Web of Science ®Google Scholar
• WILLETT CG, BOUCHER Y, DI TOMASO E et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. (2004) 10:145–147.
   PubMed Web of Science ®Google Scholar
• RAIVIASWAMY B, SHAPIRO CL: Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer. Clin. Breast Cancer (2003) 4:292–294.
   PubMedGoogle Scholar
• CHEN HX:. Expanding the clinical development of bevacizumab. Oncologist (2004) 9 (Suppl. 1):27–35.
   PubMed Web of Science ®Google Scholar
• HOLASH J, DAVIS S, PAPADOPOULOS N et al.: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA (2002) 99:11393–11398.
   PubMed Web of Science ®Google Scholar
• HUANG J, FRISCHER JS, SERUR A et al.: Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl Acad. Sci. USA (2003) 100:7785–7790.
   PubMed Web of Science ®Google Scholar
• BYRNE AT, ROSS L, HOLASH J et al.: Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. (2003) 9:5721–5728.
   PubMed Web of Science ®Google Scholar
• DUPONT J, SCHWARTZ L, KOUTCHER J et al.: Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously to patients with advanced solid malignancies. Proceedings of the 40th ASCO (2004) 23.
   Google Scholar
• JAYSON GC, ZWEIT J, JACKSON A et al.: Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies./ Natl. Cancer Inst. (2002) 94:1484–1493.
   Google Scholar
• ASANO M, YUKITA A, SUZUKI H: Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn. J. Cancer Res. (1999) 90:93–100.
   PubMedGoogle Scholar
• HUNT S: Technology evaluation: IMC-1C11, ImClone Systems. Curr. Opin. Md. Ther. (2001) 3:418–424.
   PubMed Web of Science ®Google Scholar
• WANG ES, TERUYA-FELDSTEIN J, WU Y, ZHU Z, HICKLIN D, MOORE MA: Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood (2004) 104(9):2893–2902.
   PubMed Web of Science ®Google Scholar
• POSEY JA, NG TC, YANG B et al.: A Phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin. Cancer Res. (2003) 9:1323–1332.
   PubMed Web of Science ®Google Scholar
• VAJKOCZY P, MENGER MD, VOLLMAR B et al.: Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor 5U5416 as assessed by intravital multi-fluorescence videomicroscopy. Neop/asia (1999) 1:31–41.
   PubMedGoogle Scholar
• KUENEN BC, ROSEN L, SMIT EF et al.: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and 5U5416 in patients with solid tumors. J. Clin. OncoL (2002) 20:1657–1667.
   PubMed Web of Science ®Google Scholar
• LAIRD AD, VAJKOCZY P, SHAWVER LK et al.: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. (2000) 60:4152–4160.
   PubMed Web of Science ®Google Scholar
• O'FARRELL AM, ABRAMS TJ, YUEN HA et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 101:3597–3605.
   Google Scholar
• MENDEL DB, LAIRD AD, XIN X et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327–337.
   PubMed Web of Science ®Google Scholar
• YEE KW, SCHITTENHELM M, O'FARRELL AM et al.: Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3-ITD positive leukemic cells. Blood (2004) 104(13):4202–4209.
   PubMed Web of Science ®Google Scholar
• MURRAY LJ, ABRAMS TJ, LONG KR et al.: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis (2003) 20:757–766.
   PubMed Web of Science ®Google Scholar
• O'FARRELL AM, FORAN JM, FIEDLER W et al.: An innovative Phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. (2003) 9:5465–5476.
   PubMed Web of Science ®Google Scholar
• FIEDLER W, SERVE H, DOHNER H et al.: A Phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood (2005) 105(3):986–993.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, DESAI J, FLETCHER JA et al.: SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Proceedings of the 40th ASCO (2004) 23.
   Google Scholar
• MOTZER RJ, RINI BI, MICHAELSON MD et al.: 5U011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a Phase II trial. Proceedings of the 40th ASCO (2004) 23.
   Google Scholar
• DREVS J, MULLER-DRIVER R, WITTIG C et al.: PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. (2002) 62:4015–4022.
   PubMed Web of Science ®Google Scholar
• MORGAN B, THOMAS AL, DREVS J et al.: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J. Clin. OncoL (2003) 21:3955–3964.
   PubMed Web of Science ®Google Scholar
• WEDGE SR, OGILVIE DJ, DUKES M et al.: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. (2002) 62:4645–4655.
   PubMed Web of Science ®Google Scholar
• BATES D: ZD-6474. AstraZeneca. Curr. Opin. Investig. Drugs (2003) 4:1468–1472.
   PubMedGoogle Scholar
• MEDINGER M, MROSS K, ZIRRGIEBEL U et al.: Phase I dose escalating study of the highly potent VEGF eceptor kinase inhibitor, azd2171, in patients with advanced cancers with liver metastases. Proceedings of the 40th ASCO (2004) 23.
   Google Scholar
• O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88:277–285.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, HOLMGREN L, SHING Y et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 79: 315–328.
   Google Scholar
• THOMAS JP, ARZOOMANIAN RZ, ALBERTI D et al.: Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. OncoL (2003) 21:223–231.
   PubMed Web of Science ®Google Scholar
• BOEHM T, FOLKMAN J, BROWDER T, O'REILLY MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390:404–407.
   PubMed Web of Science ®Google Scholar
• WESTPHAL JR: Technology evaluation:ABT-510, Abbott. Curr. Opin. MoL Ther. (2004) 6:451–457.
   PubMed Web of Science ®Google Scholar
• REIJERKERK A. VOEST EE, GEBBINK MF: No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. Eur. J. Cancer (2000) 36:1695–1705.
   PubMed Web of Science ®Google Scholar
• PATEL SR, JENKINS J, PAPADOPOLOUS N et al.: Pilot study of vitaxin-an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer (2001) 92:1347–1348.
   PubMed Web of Science ®Google Scholar
• POSEY JA, KHAZAELI MB, DEL GROSSO A et al.: A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti-av133) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm. (2001) 16:125–132.
   PubMed Web of Science ®Google Scholar
• BURKE PA, DE NARDO SJ, MIERS LA, LAMBORN KR, MATZKU S, DE NARDO GL: Cilengitide targeting of a(v)13(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. (2002) 62:4263–4272.
   PubMed Web of Science ®Google Scholar
• ESKENS FA, DUMEZ H, HOEKSTRA R et al.: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins av133 and av135 in patients with advanced solid tumours. Eur. j Cancer (2003) 39:917–926.
   PubMed Web of Science ®Google Scholar
• RAGUSE JD, GATH HJ, BIER J, RIESS H, OETTLE H: Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral OncoL (2004) 40:228–230.
   PubMed Web of Science ®Google Scholar
• WENG DE, USMAN N: Angiozyme: a novel angiogenesis inhibitor. Curr. OncoL Rep. (2001) 3:141–146.
   PubMedGoogle Scholar
• SANDBERG JA, PARKER VP, BLANCHARD KS et al.: Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J. Clin. PharmacoL (2000) 40:1462–1469.
   PubMed Web of Science ®Google Scholar
• KUMAR S, WITZIG TE, RAJKUMAR SV: Thalidomid: current role in the treatment of non-plasma cell malignancies. J. Clin. OncoL (2004) 22:2477–2488.
   PubMed Web of Science ®Google Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. NatL Acad. Sci. USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• VERHEUL HM, PANIGRAHY D, YUAN J, D'AMATO RJ: Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br. J. Cancer (1999) 79: 114–118.
   Google Scholar
• SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N EngL Med. (1999) 341:1565–1571.
   PubMed Web of Science ®Google Scholar
• SILLS AK Jr, WILLIAMS JI, TYLER BM et al.: Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res. (1998) 58:2784–2792.
   PubMed Web of Science ®Google Scholar
• HAO D, HAMMOND LA, ECKHARDT SG et al.: A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor. Clio. Cancer Res. (2003) 9:2465–2471.
   PubMed Web of Science ®Google Scholar
• KEYES KA, MANN L, SHERMAN M et al.:LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother. Pharmacol. (2004) 53:133–140.
   PubMed Web of Science ®Google Scholar
• DEMICHELI R, TERENZIANI M, VALAGUSSA P, MOLITERNI A. ZAMBETTI M, BONADONNA G: Local recurrences following mastectomy: support for the concept of tumor dormancy./ Nail. Cancer Inst. (1994) 86:45–48.
   PubMed Web of Science ®Google Scholar
• DEMICHELI R, ABBATTISTA A, MICELI R, VALAGUSSA P, BONADONNA G: Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res. Treat. (1996) 41:177–185.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J, HANAHAN D: Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp. (1991) 22:339–347.
   PubMedGoogle Scholar
• WEIDNER N: Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J. PathoL (1998) 184:119–122.
   PubMed Web of Science ®Google Scholar
• WEIDNER N: Angiogenesis as a predictor of clinical outcome in cancer patients. Hum. PathoL (2000) 31:403–405.
   PubMed Web of Science ®Google Scholar
• VAN'T VEER LJ, DAI H, VAN DE VIJVER MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 415:530–536.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin. OncoL (2002) 29:3–9.
   PubMed Web of Science ®Google Scholar
• TEICHER BA, SOTOMAYOR EA, HUANG ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. (1992) 52:6702–6704.
   PubMed Web of Science ®Google Scholar
• XU Y, WAHNER AE, NGUYEN PL: Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate. Arch. PathoL Lab Med. (2004) 128:980–985.
   PubMed Web of Science ®Google Scholar
• SULLIVAN DC, BICKNELL R: New molecular pathways in angiogenesis. Br. J. Cancer (2003) 89:228–231.
   PubMed Web of Science ®Google Scholar
• LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N EngL J. Med. (2004) 350:2129–2139.
   PubMed Web of Science ®Google Scholar
• ANIDO J, MATAR P, ALBANELL J et al.: ZD1839, a specific epidermal growth factor receptor (EGER) tyrosine kinase inhibitor, induces the formation of inactive EGER/ HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clio. Cancer Res. (2003) 9:1274–1283.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, MEROPOL NJ, LOEHRER PJ Sr, NEEDLE MN, KOPIT J, MAYER RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clio. Oncol. (2004) 22:1201–1208.
   PubMed Web of Science ®Google Scholar
• HAINS WORTH JD, SOSMAN JA, SPIGEL DR et al.: Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). j Clio. OncoL, 2004 ASCO Annual Meeting Proceedings (2004) 22.
   Google Scholar